Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Huntington's disease (HD) is a hereditary neurodegenerative condition with no therapeutic intervention known to alter disease progression, but several trials are ongoing and biomarkers of disease progression are needed. Tau is an axonal protein, often altered in neurodegeneration, and recent studies pointed out its role on HD neuropathology. Our goal was to study whether cerebrospinal fluid (CSF) tau is a biomarker of disease progression in HD. After informed consent, healthy controls, pre‐symptomatic and symptomatic gene expansion carriers were recruited from two HD clinics. All participants underwent assessment with the Unified HD Rating Scale ’99 (UHDRS). CSF was obtained according to a standardized lumbar puncture protocol. CSF tau was quantified using enzyme‐linked immunosorbent assay. Comparisons between two groups were tested using ancova. Pearson's correlation coefficients were calculated for disease progression. Significance level was defined as p < 0.05. Seventy‐six participants were included in this cross‐sectional multicenter international pilot study. Age‐adjusted CSF tau was significantly elevated in gene expansion carriers compared with healthy controls (p = 0.002). UHDRS total functional capacity was significantly correlated with CSF tau (r = −0.29, p = 0.004) after adjustment for age, and UHDRS total motor score was significantly correlated with CSF tau after adjustment for age (r = 0.32, p = 0.002). Several UHDRS cognitive tasks were also significantly correlated with CST total tau after age‐adjustment. This study confirms that CSF tau concentrations in HD gene mutation carriers are increased compared with healthy controls and reports for the first time that CSF tau concentration is associated with phenotypic variability in HD. These conclusions strengthen the case for CSF tau as a biomarker in HD. image In the era of novel targeted approaches to Huntington's disease, reliable biomarkers are needed. We quantified Tau protein, a marker of neuronal death, in cerebrospinal fluid and found it was increased in patients with Huntington's disease and predicted motor, cognitive, and functional disability in patients. It is therefore likely to be a biomarker of disease progression, and possibly of therapeutic response. Read the Editorial Highlight for this article on page 9.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.5 · Cited by 1,641
Self-citationTau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
Huntington disease: Clinical care and evaluation
Shoulson, I., & Fahn, S. (1979) · Neurology · doi:10.1212/wnl.29.1.1 · Cited by 746
Huntington's disease is a four-repeat tauopathy with tau nuclear rods
Fernández-Nogales, M., Cabrera, J. R., Santos-Galindo, M., Hoozemans, J. J. M., Ferrer, I., Rozemuller, A. J. M., Hernández, F., Avila, J., & Lucas, J. J. (2014) · Nature Medicine · doi:10.1038/nm.3617 · Cited by 231 · cited 1×
“Recently, two independent groups showed that human HD, while principally a ‘huntingtinopathy’, was also in effect a secondary tauopathy, with tau isoform imbalances, increased total tau, nuclear tau deposits, and tau co-localization with mHTT (Fernandez-Nogales et al. 2014; Vuono et al. 2015).”
Cited by
Huntington's disease: a clinical review
McColgan, P., & Tabrizi, S. J. (2018) · European Journal of Neurology · doi:10.1111/ene.13413 · Cited by 1,089
Self-citationHuntington disease: new insights into molecular pathogenesis and therapeutic opportunities
Tabrizi, S. J., Flower, M. D., Ross, C. A., & Wild, E. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0389-4 · Cited by 538
Self-citationByrne, L. M., Rodrigues, F. B., Blennow, K., Durr, A., Leavitt, B. R., Roos, R. A. C., Scahill, R. I., Tabrizi, S. J., Zetterberg, H., Langbehn, D., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30124-2 · Cited by 364
Self-citationHuntingtin Lowering Strategies for Disease Modification in Huntington’s Disease
Tabrizi, S. J., Ghosh, R., & Leavitt, B. R. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.039 · Cited by 337
Self-citation(2018) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-63233-3.00017-8 · Cited by 122
Self-citationCerebrospinal fluid inflammatory biomarkers reflect clinical severity in Huntington's disease
Rodrigues, F. B., Byrne, L. M., McColgan, P., Robertson, N., Tabrizi, S. J., Zetterberg, H., & Wild, E. J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163479 · Cited by 79
Self-citationMutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease
Caron, N. S., Banos, R., Yanick, C., Aly, A. E., Byrne, L. M., Smith, E. D., Xie, Y., Smith, S. E. P., Potluri, N., Findlay Black, H., et al. (2021) · The Journal of Neuroscience · doi:10.1523/jneurosci.1865-20.2020 · Cited by 66
Self-citationTau or neurofilament light—Which is the more suitable biomarker for Huntington’s disease?
Niemelä, V., Landtblom, A.-M., Blennow, K., & Sundblom, J. (2017) · PLOS ONE · doi:10.1371/journal.pone.0172762 · Cited by 63
Tau and neurofilament light‐chain as fluid biomarkers in spinocerebellar ataxia type 3
Garcia‐Moreno, H., Prudencio, M., Thomas‐Black, G., Solanky, N., Jansen‐West, K. R., Hanna AL‐Shaikh, R., Heslegrave, A., Zetterberg, H., Santana, M. M., Pereira de Almeida, L., et al. (2022) · European Journal of Neurology · doi:10.1111/ene.15373 · Cited by 49
Self-citationFaulty splicing and cytoskeleton abnormalities in Huntington's disease
Fernández‐Nogales, M., Santos‐Galindo, M., Hernández, I. H., Cabrera, J. R., & Lucas, J. J. (2016) · Brain Pathology · doi:10.1111/bpa.12430 · Cited by 41
Metadata
- Authors
- Rodrigues, F. B., Byrne, L., McColgan, P., Robertson, N., Tabrizi, S. J., Leavitt, B. R., Zetterberg, H., & Wild, E. J.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2016-09-20
- Volume
- 139
- Issue
- 1
- Pages
- 22-25
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2470063159
- Cited by
- 80
- References
- 4
- FWCI
- 4.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.